Histone methyltransferase DOT1L maintains identity and restricts cytotoxic potential of CD8 T cells
Authors:
- Muddassir MalikMMMuddassir Malik
- Willem-Jan de LeeuwWLWillem-Jan de Leeuw
- Muhammad Assad AslamMAMuhammad Assad Aslam
- Eliza Mari Kwesi-MaliepaardEKEliza Mari Kwesi-Maliepaard
- Teun van Den BrandTBTeun van Den Brand
- Bram van Den BroekBram van Den Broek
- Maxime KempersMaxime Kempers
- Liesbeth HoekmanLHLiesbeth Hoekman
- Elzo de WitEWElzo de Wit
- Jannie BorstJBJannie Borst
Preprint
Abstract
The histone methyltransferase DOT1L is emerging as a central epigenetic regulator in immune cells. Loss of DOT1L during development of CD8 T cells in vivo leads to gain of memory-features but has also been reported to compromise CD8 T cell viability and activity. Here, we determined the cell-intrinsic role of DOT1L in mature mouse CD8 T cells. After conditional deletion of Dot1L in vitro, CD8 T cells retained in vivo proliferative capacity and anti-tumor reactivity. Moreover, Dot1L knock-out CD8 T cells showed increased antigen-specific cytotoxicity towards tumor cells in vitro. Mechanistically, loss of DOT1L resulted in an altered cell-identity program with loss of T-cell and gain of NK-cell features. These transcriptional changes were mediated by loss of DOT1L methyltransferase activity in a dose-dependent manner. Our findings show that ablation of DOT1L activity in mature CD8 T cells is well-tolerated and rewires their cell identity towards the NK-cell lineage, concomitantly enhancing intrinsic cytotoxic capacity. Highlights: Differentiation and identity of cytotoxic T cells depend on the methyltransferase DOT1L DOT1L intrinsically limits the cytotoxic activity of mature CD8 T cells DOT1L prohibits the acquisition of NK cell features in CD8 T cells DOT1L maintains CD8 T cell identity through its catalytic activity in a dose-dependent mannerKeywords
All Related Versions
- Published version: Science Advances, 11 (50), eadw1289.
This publication has 87 references indexed in Scilit:
- Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunityCell, 2024
- Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cellsCancer Immunology, Immunotherapy, 2024
- Separate signaling events control TCR downregulation and T cell activation in primary human T cellsImmunity, Inflammation and Disease, 2020
- CD160 expression on CD8+ T cells is associated with active effector responses but limited activation potential in pancreatic cancerCancer Immunology, Immunotherapy, 2020
- CD5 blockade enhances ex vivo CD8+ T cell activation and tumour cell cytotoxicityEuropean Journal of Immunology, 2020
- CD69: from activation marker to metabolic gatekeeperEuropean Journal of Immunology, 2017
- The upstreams and downstreams of H3K79 methylation by DOT1LChromosoma, 2016
- Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L InhibitorCancer Cell, 2011
- Identification of committed NK cell progenitors in adult murine bone marrowEuropean Journal of Immunology, 2001
- T cell receptor antagonist peptides induce positive selectionCell, 1994